The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations

Documenti analoghi

• Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
  di: Long, Lu, et al.
  Pubblicazione: (2015)
• Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension
  di: Drake, Kylie M., et al.
  Pubblicazione: (2013)
• The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension
  di: Ormiston, Mark L., et al.
  Pubblicazione: (2015)
• Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells
  di: Upton, Paul D., et al.
  Pubblicazione: (2009)
• Hematopoietic stem cell transplantation alters susceptibility to pulmonary hypertension in Bmpr2-deficient mice
  di: Crosby, Alexi, et al.
  Pubblicazione: (2018)